Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

118.44 -0.06 (-0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
66 67 Next >
Gilead Sciences's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
A Closer Look at Gilead Sciences's Options Market Dynamics
 
Via Benzinga
Where Gilead Sciences Stands With Analysts
 
Via Benzinga
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Buying the dip in high-yield Gilead Sciences
Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return 
Via MarketBeat
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today
 
Via Benzinga
This Is What Whales Are Betting On Gilead Sciences
 
Via Benzinga
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's  
Via Benzinga
Gilead Sciences Announces Third Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
The biotech company makes three notable treatments for cancer. 
Via Investor's Business Daily
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry
 
Via Benzinga
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. 
Via Benzinga
Topics Economy Stocks
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and... 
Via Benzinga
Topics Bonds Economy
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
From Gilead Sciences, Inc.
Via Business Wire
Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook
Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.  
Via Benzinga
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
From Gilead Sciences, Inc.
Via Business Wire
3 Pharma Stocks That Are Screaming Buys in October
Each company delivers an above-average dividend and revenue growth. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
7 Healthcare Stocks to invest in for a Healthy Future
Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners. 
Via InvestorPlace
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.